Impact of Frailty on Mortality and Hospitalization in Chronic Heart Failure: A Systematic Review and Meta-Analysis

Xiaobo Yang, MB; Josep Lupón, MD, PhD; Maria T. Vidán, MD, PhD; Caleb Ferguson, RN, PhD; Paloma Gastellurutia, PhD; Phillip J. Newton, BN, PhD; Peter S. Macdonald, MBBS, MD, PhD; Héctor Bueno, MD, PhD; Antoni Bayés-Genís, MD, PhD; Jean Woo, MD; Erik Fung, MB, ChB, PhD

Background—Although frailty has been associated with increased risks for hospitalization and mortality in chronic heart failure, the precise average effect remains uncertain. We performed a systematic review and meta-analysis to summarize the hazards for mortality and incident hospitalization in patients with heart failure and frailty compared with those without frailty and explored the heterogeneity underlying the effect size estimates.

Methods and Results—MEDLINE, EMBASE, and Cochrane databases were queried for articles published between January 1966 and March 2018. Predefined selection criteria were used. Hazard ratios (HRs) were pooled for meta-analyses, and where odds ratios were used previously, original data were recalculated for HR. Overlapping data were consolidated, and only unique data points were used. Study quality and bias were assessed. Eight studies were included for mortality (2645 patients), and 6 studies were included for incident hospitalization (2541 patients) during a median follow-up of 1.82 and 1.12 years, respectively. Frailty was significantly associated with an increased hazard for mortality (HR, 1.54; 95% confidence interval, 1.34–1.75; P<0.001) and incident hospitalization (HR, 1.56; 95% confidence interval, 1.36–1.78; P<0.001) in chronic heart failure. The Fried phenotype estimated a 16.9% larger effect size than the combined Fried/non-Fried frailty assessment for the end point of mortality (HR, 1.80; 95% confidence interval, 1.41–2.28; P<0.001), but not for hospitalization (HR, 1.57; 95% confidence interval, 1.30–1.89; P<0.001). Study heterogeneity was found to be low (I²=0%), and high quality of studies was verified by the Newcastle-Ottawa scale.

Conclusions—Overall, the presence of frailty in chronic heart failure is associated with an increased hazard for death and hospitalization by ≈1.5-fold. (J Am Heart Assoc. 2018;7:e008251. DOI: 10.1161/JAHA.117.008251)

Key Words: chronic heart failure • frailty • hospitalization • meta-analysis • mortality

Frailty is a complex systemic syndrome that has been associated with poor outcomes, including increased rates of mortality and hospitalization in frail patients with heart failure (HF) compared with those without frailty.1–7 More commonly observed in association with advanced age,1 frailty can also affect young patients with HF and can be reversible.

From the Department of Medicine and Therapeutics (X.Y., J.W., E.F.), CARE Programme, Lui Che Woo Institute of Innovative Medicine (E.F) and Gerald Choa Cardiac Research Centre (E.F.), Faculty of Medicine, and CUHK Jockey Club Institute of Ageing (J.W.), The Chinese University of Hong Kong, Hong Kong SAR; Laboratory for Heart Failure and Circulation Research, Li Ka Shing Institute of Health Sciences, Prince of Wales Hospital, Hong Kong SAR (X.Y., E.F.); Cardiology Department, Hospital Universitari Germans Trias i Pujol, Badalona, Spain (J.L., A.B.-G.); Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain (J.L., A.B.-G.); CIBERCV, Instituto de Salud Carlos III, Madrid, Spain (J.L., P.G., A.B.-G.); Department of Geriatrics, Instituto de Investigación iISGM and CIBERFES Hospital General Universitario Gregorio Marañón, Madrid, Spain (M.T.V.); Universidad Complutense de Madrid, Madrid, Spain (M.T.V., H.B.); Western Sydney Nursing and Midwifery Research Centre, Western Sydney University and Western Sydney Local Health District, Sydney, Australia (C.F., P.J.N.); Fundación Institut d’Investigació en Ciències de la Salut Germans Trias i Pujol, Badalona, Spain (P.G.); Heart and Lung Transplant Unit, St Vincent’s Hospital, University of New South Wales, Sydney, Australia (P.S.M.); Transplantation Research Laboratory, Victor Chang Cardiac Research Institute, Sydney, Australia (P.S.M.); Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain (H.B.); Instituto de Investigación i+12 and Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain (H.B.); and School of Public Health, Imperial College London, London, United Kingdom (E.F.).

Accompanying Tables S1 through S3 and Figures S1, S2 are available at https://www.ahajournals.org/doi/suppl/10.1161/JAHA.117.008251
Correspondence to: Erik Fung, MB, ChB, PhD, Division of Cardiology, Department of Medicine and Therapeutics, Faculty of Medicine, The Chinese University of Hong Kong, 9/F, Lui Che Woo Clinical Sciences Building, Prince of Wales Hospital, 30–32 Ngan Shing St, Shatin, New Territories, Hong Kong SAR. E-mail: e.fung@cuhk.edu.hk.
Received December 2, 2017; accepted October 12, 2018.
© 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
Clinical Perspective

What Is New?

- This meta-analysis is the first to summarize the literature and report on a 1.5-fold increase in the adverse outcome of death or incident hospitalization associated with frailty in patients with chronic heart failure during a follow-up of <2 years.
- The Fried phenotype, an often-used frailty assessment scale originally developed from the Cardiovascular Health Study, estimated a higher mortality rate of 16.9% compared with that of the combined (Fried and non-Fried) assessment, whereas the estimate for incident hospitalization was indistinct between Fried and the combined assessments.

What Are the Clinical Implications?

- Since publication of “Knowledge Gaps in Cardiovascular Care of the Older Adult Population: A Scientific Statement From the American Heart Association, American College of Cardiology, and American Geriatrics Society” (2016), and the Geriatric Cardiology Council document of the American College of Cardiology (2018), there have been increasing efforts to tackle heart failure and geriatric cardiovascular disease using multidomain approaches.
- The Fried phenotype is simple to use, provides prognostic information, and assesses for domain-based physiological insufficiencies that may lend itself to daily clinical practice and screening for latent chronic heart failure.
- Frailty associated with heart failure may be reversible and a target for intervention.

after heart transplantation \(^8\) or heart function replacement.\(^9\) Characterizing frailty status in patients with HF may provide clinicians an indicator for gauging disease severity, prognosis, and disease progression or reversal.

Although most studies have shown increased risks for hospitalization and mortality in chronic HF,\(^2–7\) offset by 2 relatively small studies with borderline neutral results,\(^10,11\) the precise average effect of frailty has not previously been summarized with certainty. Recently, a systematic review included a total of 8 articles from 2004 to 2014 and suggested that patients with HF and frailty had increased risks for adverse outcomes.\(^12\) However, 2 of 8 articles\(^5,13–15\) in that study contained data from overlapping studies (ie, double counting), and no meta-analysis was performed. Since 2014, 6 additional independent studies\(^2–4,11,16,17\) with potential to be included in a meta-analysis have been published. Recently, a systematic review and meta-analysis has summarized data on the prevalence of HF-associated frailty from 26 studies at 44.5% after removal of 14 overlapping studies.\(^18\) However, that study did not assess the impact or effect size of frailty on adverse outcomes, including death and hospitalization, and included patients with acute HF and those receiving cardiac resynchronization therapy, left ventricular assist device (LVAD), or heart transplant.\(^18\) In this study, we have carefully summarized the existing evidence, explored for heterogeneity, and completed the first meta-analysis of frailty on the hazards of mortality and incident hospitalization in patients with chronic HF.

Methods

Data Sources and Search Strategy

The data that support the findings of this study are available from the corresponding author on reasonable request. From October 2016 to April 2018, we searched MEDLINE, EMBASE, and the Cochrane databases for articles published between January 1966 and March 2018. Study design (Figure 1 and Figure S1) and data reporting were compliant with MOOSE, as recommended in the EQUATOR Network guidelines.\(^19,20\) Institutional Review Board approval was not required for this systematic review and meta-analysis.

Eligibility Criteria

The following Medical Subject Headings or MeSH search terms were used: “frailty AND heart failure,” “frail AND heart failure,” “fragility AND heart failure,” “gait speed AND heart failure,” “grip strength AND heart failure,” “weight loss AND heart failure,” and “cognitive frailty AND heart failure.” Frailty is a term used by some European investigators with whom we have individually confirmed about its use in their publications as being synonymous with frailty for the purpose of this study. Literature search was independently performed by 2 reviewers (E.F. and X.Y.), according to a prespecified workflow. Conflicting findings were resolved by a third researcher (J.W.). The inclusion criteria were as follows: (1) frailty assessed using validated assessment instruments; (2) confirmed diagnosis of HF on the basis of international criteria and guideline definitions\(^21,22\); (3) human individuals; and (4) articles in English. The exclusion criteria were as follows: (1) unpublished data, abstracts, conference proceedings, comments, letters, correspondences, editorials, or duplicates; (2) studies without any relevance to the clinical outcomes of hospitalization and mortality; (3) studies that investigated the effects of medical or surgical intervention, including cardiac resynchronization therapy, LVAD, and cardiac transplantation; (4) data on acute HF; and (5) non-English articles.

Data Extraction

The main clinical outcomes in this meta-analysis were all-cause mortality and hospitalization. Where data on all-cause hospitalization were not available,\(^3\) cardiac hospitalization
was used. A structured data form was used to organize information\(^2\)\(^{-7,10,11,13\text{--}17,23\text{--}37}\) (Table). Two reviewers (E.F. and X.Y.) extracted the raw data and independently evaluated study quality (described later).

**Data Synthesis and Statistical Analysis**

The effect sizes of risks were reanalyzed and recalculated as hazards, pooled, and represented by adjusted or unadjusted hazard ratios (HRs) for the clinical outcomes of all-cause mortality or hospitalization in frail and nonfrail patients with chronic HF. When available, all-cause rather than cardiac hospitalization was used. This is justified by evidence in the literature that hospitalizations secondary to HF with preserved left ventricular ejection fraction (EF) are often attributable to complex comorbidities.\(^{21,22}\) Of 6 studies included in the meta-analysis of frailty on incident hospitalization, 5 used all-cause hospitalization and 1 used cardiac hospitalization\(^5\) as end points. Where possible, adjusted, rather than unadjusted, HRs were used (Table S1).

To standardize classification of frailty/nonfrailty status, we reclassified prefrailty, a nonexistent category in some frailty assessment scales\(^{38,39}\) as nonfrailty. To minimize data redundancy and double counting,\(^40\) we contacted authors of the original studies for clarification and data reanalysis, where necessary. Among a total of 10 groups authoring 20 studies, 8 groups responded to our query with clarification and/or assisted in reanalysis (response rate, 80%). Where data redundancy from overlapping studies was suspected or in cases in which the original authors could not be reached, we proceeded to remove those articles from further analysis. The research group of Bayés-Genís, Lupón, and Gastelurrutia consolidated their cohort data from 3 publications and reanalyzed risk estimates.\(^3,15,34\)

Originally presented as odds ratios in the study of Vidán and colleagues,\(^4\) the risk for rehospitalization was recalculated as HRs using data from telephone interviews at 1, 3, 6, and 12 months after hospital discharge. For 66 patients in that study who did not have the exact dates of rehospitalization, the time to hospitalization was imputed using the calculated mean time to hospitalization from the remaining 340 patients. The data on mortality and hospitalization from the original article by Ferguson and colleagues were newly calculated and presented as HRs.\(^{16}\)
Table. Characteristics of Studies Reporting on Frailty and Chronic HF

| Source (First Author) | Reference No. | Y     | Country       | Study Period            | Design              | Type of Patients                                                                 | No. of Patients | Age, Mean±SD, y | Men, n (%)     | Prevalence of Frailty, % (n/Total) |
|-----------------------|---------------|-------|---------------|-------------------------|---------------------|---------------------------------------------------------------------------------|----------------|----------------|----------------|----------------------------------|
| Boxer*                | 5             | 2010  | United States | 2004–2005, follow-up in 2008 | Prospective         | Patients with HF, aged ≥60 y                                                   | 59             | 78±12          | 42 (71.2) | 25.4 (15/59)                               |
| Cacciatore*           | 6             | 2005  | Italy         | 1992                    | Prospective (secondary analysis) | Outpatients with HF, aged ≥65 y                                               | 120            | 75.9±6.7       | 48 (40)      | 15 (18/120)                                 |
| Denfeld               | 23            | 2017  | United States | 2015–2016               | Cross-sectional     | Inpatients and outpatients with HF                                             | 49             | 57.4±9.7       | 33 (67)      | 49.0 (24/49)                               |
| Ferguson*             | 16            | 2017  | Australia     | 2013                    | Prospective         | Inpatients with HF and AF, 100%                                               | 137            | 72±16          | 87 (63.5)    | 63 (58/92)                                   |
| Gastelurrutia*        | 3             | 2014  | Spain         | 2001–2012               | Prospective         | Outpatients with HF                                                            | 1314           | 66.7±12.4      | 950 (72.3)   | 44.2 (581/1314)                            |
| González-Moneo        | 17            | 2016  | Spain         | 2005–2010               | Prospective         | Outpatients with HF                                                            | 525            | 71±11          | 320 (61)     | 55 (279/509)                                |
| Khandelwal†           | 24            | 2012  | India         | N/A                     | Prospective (secondary analysis) | Inpatients with HF                                                            | 30             | N/A            | N/A           | 76.7 (23/30)                                |
| Madan*                | 11            | 2016  | United States | 2011–2013               | Prospective         | Outpatients with advanced HF, aged ≥65 y, with 6-min walk distance of <300 m | 40             | 74.9±6.5       | 17 (42.5)     | 65 (26/40)                                  |
| McNallan‡             | 7             | 2013  | United States | 2007–2011               | Prospective         | Inpatients and outpatients with HF                                             | 448            | 73.2±13.3      | 257 (57.4)   | 18.8 (84/448)                              |
| McNallan*             | 10            | 2013  | United States | 2007–2011               | Prospective         | Inpatients and outpatients with HF                                             | 223            | 71.1±13.9      | 135 (60.5)   | 20.6 (46/223)                             |
| Newman†               | 25            | 2001  | United States | 1989–1990               | Prospective, observational (secondary analysis) | Outpatients with HF, aged ≥65 y                                               | 181            | N/A            | N/A           | 22.7 (41/181)                              |
| Nishiguchi            | 26            | 2016  | Japan         | N/A                     | Prospective         | Patients with HF, aged ≥60 y                                                  | 206            | 73.7±7.3       | 143 (69.4)   | 16.5 (34/206)                              |

Continued
| Reference | No. Y | Country | Study Period | Design | Type of Patients | Frailty Assessment | Sex, n (%) | Prevalence of Frailty, % (n/Total) |
|-----------|-------|---------|--------------|--------|-----------------|-------------------|-------------|------------------------------------|
| Parmar    | 27    | United Kingdom | 2015         | NA     | Retrospective   | CSHA              | Men, n (%) | 75.6 (197/261)                     |
| Reeves    | 28    | United States | 2016         | NA     | Prospective     | Fried phenotype   | N/A         | 69.1 (125/181)                     |
| Rodriguez-Pascual | 2   | Spain | 2017          | NA     | Prospective     | Fried phenotype   | 133 (93)    | 77.6 (100/128)                     |
| Uchmanowicz | 29  | Poland | 2018         | NA     | Prospective     | Fried phenotype   | 330 (222/330) | 72.1 ±7.9                         |
| Vidan     | 31    | Spain | 2016          | NA     | Prospective     | Fried phenotype   | 416         | 62.1 (256/416)                     |
| Woods     | 32    | Spain | 2010–2012     | NA     | Prospective     | Fried phenotype   | 549         | 68.1 ±8.7                         |
| Kenny     | 33    | Spain | 2001          | NA     | Prospective     | Fried phenotype   | 1405 (1405) | 67.2 ±12.4                        |
| Lupón     | 34    | Spain | 2008          | NA     | Prospective     | Fried phenotype   | 662        | 68 (Median)                        |

*Overlapping studies with data redundancy*
Results from eligible studies were pooled and meta-analyzed using a random-effects model with inverse-variance weighting. Heterogeneity of studies was assessed using Cochrane’s Q statistic and $I^2$. Prespecified $I^2$ threshold values of 25%, 50%, and 75% were used to indicate low, moderate, and high levels of heterogeneity, respectively. A 2-tailed $P<0.05$ was considered statistically significant. Analyses were performed using Review Manager 5.3 (The Cochrane Collaboration) and R 3.3.3 (R Foundation).

**Assessment of Publication Bias and Study Quality**

Publication bias was assessed using funnel plots and Duval-Tweedie’s trim-and-fill test (Figure S2).

**Results**

**Search and Study Selection**

Our query to EMBASE, MEDLINE, and Cochrane databases returned 6886 records (Figure 1 and Figure S1). After further screening and evaluation, 6641 irrelevant records and 217 ineligible full-text articles were excluded. Among 28 eligible articles,8–17,19–23,37 8 and 6 unique studies were finally included in the meta-analysis for all-cause mortality and incident hospitalization, respectively (Figure 1 and Table).

**Characteristics of Patients With Chronic HF**

Among studies that reported on the prevalence rates of atrial fibrillation, ischemic heart disease (coronary artery disease), hypertension, and/or diabetes mellitus, the respective median prevalence rates were 53% (quartile 1–quartile 3, 46.5%–62.2%), 44.5% (quartile 1–quartile 3, 26.9%–54.5%), 80% (quartile 1–quartile 3, 64.0%–87.9%), and 38.4% (quartile 1–quartile 3, 34.8%–47.0%). The median prevalence rate of frailty from 17 of 19 nonoverlapping studies was 49.0% (quartile 1–quartile 3, 21.7–64.9); data were unavailable from 2 studies.

**Frailty Is Significantly Associated With Increased Mortality in Chronic HF**

On the basis of data from 8 unique studies, the presence of frailty is significantly associated with an increased hazard for mortality in chronic HF (HR, 1.54; 95% confidence interval [CI], 1.34–1.75; $P<0.001$) (Figure 2A and Table S2). The median duration of follow-up for 2645 patients in the 8 studies8–17,19–23,37 was 1.82 years (quartile 1–quartile 3, 1.0–3.9 years). In studies that used only the Fried phenotype for frailty assessment (n=5 studies;
### Table A

| Study or Subgroup | Frail | Non-frail | HR | HR | HR |
|-------------------|-------|-----------|----|----|----|
|                  | Total | Total     | Weight | IV, Random, 95% CI | IV, Random, 95% CI |
| Boxer et al, 2010 | 0.4574 | 0.1621 | 15 | 44 | 17.6% | 1.58 [1.15, 2.17] |
| Cacciatore et al, 2005 | 0.392 | 0.18 | 18 | 102 | 14.2% | 1.48 [1.04, 2.11] |
| Ferguson et al, 2017 | 1.3137 | 0.5524 | 52 | 32 | 1.5% | 3.72 [1.26, 10.98] |
| Gasteiruirta et al, 2014 | 0.3221 | 0.093 | 581 | 733 | 53.1% | 1.38 [1.15, 1.66] |
| Madan et al, 2016 | 0.7793 | 0.7938 | 26 | 14 | 0.7% | 2.18 [0.46, 10.33] |
| McNallan et al, 2013 | 0.7129 | 0.3689 | 46 | 69 | 3.4% | 2.04 [0.99, 4.20] |
| Rodriguez-Pascual et al, 2017 | 0.7655 | 0.2849 | 286 | 211 | 5.7% | 2.15 [1.23, 3.76] |
| Vidan et al, 2016 | 0.7561 | 0.3513 | 316 | 100 | 3.7% | 2.13 [1.07, 4.24] |
| Total (95% CI) | 1340 | 1305 | 100.0% | 1.54 [1.34, 1.75] |

Heterogeneity: Tau² = 0.00; Chi² = 7.01, df = 7 (P = 0.43); I² = 0%
Test for overall effect: Z = 6.31 (P < 0.00001)

### Table B

| Study or Subgroup | Frail | Non-frail | HR | HR |
|-------------------|-------|-----------|----|----|
|                  | Total | Total     | Weight | IV, Random, 95% CI |
| Boxer et al, 2010 | 0.4574 | 0.1621 | 15 | 44 | 56.5% | 1.58 [1.15, 2.17] |
| Madan et al, 2016 | 0.7793 | 0.7938 | 26 | 14 | 2.4% | 2.18 [0.46, 10.33] |
| McNallan et al, 2013 | 0.7129 | 0.3689 | 46 | 69 | 10.9% | 2.04 [0.99, 4.20] |
| Rodriguez-Pascual et al, 2017 | 0.7655 | 0.2849 | 286 | 211 | 18.3% | 2.15 [1.23, 3.76] |
| Vidan et al, 2016 | 0.7561 | 0.3513 | 316 | 100 | 12.0% | 2.13 [1.07, 4.24] |
| Total (95% CI) | 689 | 438 | 100.0% | 1.80 [1.41, 2.28] |

Heterogeneity: Tau² = 0.00; Chi² = 1.44, df = 4 (P = 0.84); I² = 0%
Test for overall effect: Z = 4.80 (P < 0.00001)

### Table C

| Study or Subgroup | Frail | Non-frail | HR | HR |
|-------------------|-------|-----------|----|----|
|                  | Total | Total     | Weight | IV, Random, 95% CI |
| Ferguson et al, 2017 | 0.157 | 0.2769 | 52 | 32 | 6.3% | 1.17 [0.68, 2.01] |
| Gasteiruirta et al, 2014 | 0.4762 | 0.1091 | 581 | 733 | 40.3% | 1.61 [1.30, 1.99] |
| Madan et al, 2016 | 0.6523 | 0.275 | 26 | 14 | 6.3% | 1.92 [1.12, 3.29] |
| McNallan et al, 2013 | 0.5008 | 0.1754 | 84 | 116 | 15.6% | 1.65 [1.17, 2.33] |
| Rodriguez-Pascual et al, 2017 | 0.5008 | 0.2023 | 286 | 211 | 11.7% | 1.65 [1.11, 2.45] |
| Vidan et al, 2016 | 0.3148 | 0.1555 | 307 | 99 | 19.8% | 1.37 [1.01, 1.86] |
| Total (95% CI) | 1336 | 1205 | 100.0% | 1.56 [1.36, 1.78] |

Heterogeneity: Tau² = 0.00; Chi² = 2.61, df = 5 (P = 0.76); I² = 0%
Test for overall effect: Z = 6.39 (P < 0.00001)

### Table D

| Study or Subgroup | Frail | Non-frail | HR | HR |
|-------------------|-------|-----------|----|----|
|                  | Total | Total     | Weight | IV, Random, 95% CI |
| Vidan et al, 2016 | 0.3148 | 0.1555 | 306 | 99 | 37.1% | 1.37 [1.01, 1.86] |
| McNallan et al, 2013 | 0.5008 | 0.1754 | 84 | 116 | 29.1% | 1.65 [1.17, 2.33] |
| Rodriguez-Pascual et al, 2017 | 0.5008 | 0.2023 | 286 | 211 | 21.9% | 1.65 [1.11, 2.45] |
| Madan et al, 2016 | 0.6523 | 0.275 | 26 | 14 | 11.9% | 1.92 [1.12, 3.29] |
| Total (95% CI) | 702 | 440 | 100.0% | 1.57 [1.30, 1.89] |

Heterogeneity: Tau² = 0.00; Chi² = 1.44, df = 3 (P = 0.70); I² = 0%
Test for overall effect: Z = 4.75 (P < 0.00001)

---

**Figure 2.** Eight unique studies with nonoverlapping data. Inverse variance (IV) weighting and random-effects model were used in the meta-analysis. Reference number is shown after year of publication (see References for details). A, Effects of frailty on all-cause mortality in patients with chronic heart failure (HF). B, Effects of frailty on all-cause mortality in patients with chronic HF in 5 studies that used the Fried phenotype for frailty assessment. IV weighting and random-effects model were used in the meta-analysis. Reference number is shown after year of publication (see References for details). C, Effects of frailty on incident hospitalization in patients with chronic HF. Six unique studies with nonoverlapping data are shown. IV weighting and random-effects model were used in the meta-analysis. Reference number is shown after year of publication (see References for details). D, Effects of frailty on incident hospitalization in patients with chronic HF in 4 studies that used the Fried phenotype for frailty assessment. IV weighting and random-effects model were used in the meta-analysis. Reference number is shown after year of publication (see References for details). CI indicates confidence interval; df, degrees of freedom; HR, hazard ratio.

---

**Figure 2B,** the effect size estimate was increased by 16.9% (HR, 1.80; 95% CI, 1.41–2.28; P<0.001; n=1127 patients).

Irrespective of the frailty assessment instrument used, the level of study heterogeneity was low (I²=0%) (Figure 2A and 2B).

**Frailty Is Significantly Associated With an Increased Rate of Hospitalization in Chronic HF**

During a median follow-up of 1.12 years (quartile 1–quartile 3, 1–2 years), the presence of frailty was significantly...
associated with an increased hazard for hospitalization by 56% (adjusted HR, 1.56; 95% CI, 1.36–1.78; P<0.001; n=2541 patients in 6 studies), even after adjusting for factors in the respective studies.4–7,11,16 (Figure 2C and Table S1). In 4 studies that used Fried assessment,2,4,7,11 the estimate was, however, similar (adjusted HR, 1.57; 95% CI, 1.30–1.89; P<0.001; n=1142 patients) to the overall pooled estimate (Figure 2D). The level of heterogeneity between studies was also low (I²=0%) (Figure 2C and 2D).

Publication Bias and Study Quality

Although the effect size estimates for mortality fell within the pseudo 95% confidence limits of the funnel plot (Figure S2A), we proceeded to using the trim-and-fill test for ascertainment and found no significant difference with or without adjustment (adjusted HR, 1.48 [95% CI, 1.25–1.75] [P<0.001] 1.54 [95% CI, 1.34–1.75] [P<0.001]) (Figure S2C and Figure 2A), thereby ruling out large publication bias effects. The high quality of the included studies2–7,10,11,16 was indicated by a composite score of ≥7 on the Newcastle-Ottawa scale41 (Table S3).

Discussion

Frailty is increasingly recognized as an important target for monitoring and intervention in contemporary cardiovascular care and management.42,43 Clinical pathways using frailty assessment in management decision making and for determination of procedural eligibility have previously been shown to affect patient outcomes and provide prognostic indication of well-being and survival associated with procedures, ranging from transcatheter and surgical aortic valve replacement to heart transplantation.43–45 However, the precise negative effects of frailty on chronic HF2–7,10,11 have not been previously established with certainty.

This systematic review and meta-analysis is the first to summarize the adverse impact of hospitalization and mortality associated with frailty in chronic HF. Mortality and incident hospitalization were both significantly increased by ≈1.5-fold in >1300 patients with HF with frailty, compared with >1200 patients with HF without frailty (Figure 2). This study has reanalyzed and recalculated risk estimates as HRs, consolidated data from 3 independent sources (study cohorts from Barcelona, Spain; Madrid, Spain; and Sydney, Australia) to minimize or eliminate double counting, and focused on patients with chronic HF. Current available studies in the literature have not included any meta-analyzed data on mortality and hospitalization associated with frailty in HF.12,46 and frailty prevalence was the sole focus of another recently published meta-analysis that included patients with acute decompensated HF, patients with chronic HF, and patients receiving cardiac resynchronization therapy, LVAD, and heart transplant.18

One of the major findings in this study was the higher estimate of hazard for mortality, but not incident hospitalization, by the Fried phenotype compared with the overall pooled (combined Fried and non-Fried) estimates (Figure 2). The reason for this observation is unclear, but it can be possibly explained by the overlapping characteristics (and pathophysiological features) between functional components of the Fried phenotype (eg, progressive unintentional weight loss and weakness) and cardiac cachexia of advanced chronic HF, which carries a poor prognosis. However, the concept of cardiac cachexia cannot be simply explained by reduced body mass index alone because this relationship is complex,43 depending on the population or patient subset with HF, the cause, the pathogenesis, and the chronicity of the pathophysiological features. For instance, patients waiting for heart transplant tend to be younger, may have developed HF with reduced EF over a relatively shorter period (eg, post–viral dilated cardiomyopathy), and may have different physiological reserve levels and body composition compared with elderly patients with long-standing, chronic HF. Older adults may have more comorbidities,47 latent chronic HF48 (particularly, HF with preserved EF), and sarcopenic obesity,49 a disorder characterized by low lean skeletal muscle mass relative to abundant intermuscular adiposity. This meta-analysis was focused on patients with chronic HF and frailty outside the setting of heart function replacement or acute HF, acknowledging the variability in phenotypic expression of (or individuals’ variable resistance to) frailty, and its manifestation and reversibility across the HF spectrum.

The clinical phenotype proposed by Fried and colleagues38 in 2001 is based on the concept of aging-related failure of homeostasis in physiologic systems (or domains) represented by 5 specific items: low physical activity, fatigue, shrinkage (or unintentional weight loss over a defined period), weakness, and slowness. The 5 items of the Fried phenotype are scored out of 0–10 points, with 1 point awarded for each positive item; scores of 0, 1 to 2, and ≥3 indicate subjects in frail, prefrail, and robust states, respectively. The prefrail state may be a clinically relevant indicator of underlying cardiometabolic disorder, reduced physiological reserve, and a window of opportunity for workup and intervention before development of systemic decompensation. However, the absence of prefrailty in some frailty assessment scales precluded comparison between studies for this condition. Another major frailty concept is centered on the frailty index developed by Rockwood et al.50 The frailty index is based on a cumulative multiple deficit approach, using clinical and laboratory variables with an emphasis on the number rather than type of derangements. As noted, these and other commonly used frailty assessment tools, including the modified Fried-based FRAIL scale that obviates physical testing (eg, hand grip strength and walking tests)51 with improved clinical operationality, have been previously compared in specific settings and found to
Impact of Frailty on Chronic Heart Failure

Yang et al

can be feasible and informative for the specific purpose of this study, as supported by available evidence in the literature.

Although definitions and assessment scales do vary, there has been impetus toward a universal definition of frailty in the geriatric professional community. Currently, frailty is not routinely assessed for or systematically categorized in patients with HF. However, findings from this and other studies encourage the use of frailty assessment for risk stratification of patients with HF to inform prognosis and management decisions. Recent data from the LVAD and heart transplant literature suggest that frailty in patients with advanced HF can be reversed by intervention or organ replacement, and that frailty is not necessarily age or functional class related, suggesting that inclusion of frailty assessment in patients with HF can inform outcomes. Indeed, Jha and colleagues have shown that pre-LVAD or pretransplant frailty status has a significant impact on survival after LVAD implantation or heart transplantation.

There are several limitations in this study. First, the competing risks between hospitalization and mortality across time could not be assessed given the limitations inherent in the original studies. Second, hospitalization as an outcome measure is complex and may be HF associated, cardiac related, or unrelated to cardiovascular events. Details on hospitalization and contemporary metrics (eg, 30-day readmission and length of stay) for characterizing hospitalization were unavailable from the included studies. Future studies using standardized metrics may improve accuracy of risk estimates. Third, there were insufficient data in the available articles to perform a meta-analysis on HF subtypes (eg, HF with reduced EF and HF with preserved EF). Although some studies have shown that the adjusted survival and hospitalization rates are similar between HF subtypes, there is a need for future studies to clarify this.

In conclusion, this meta-analysis provides the first summary on the effects of frailty on mortality and hospitalization and confirms the significant negative impact of frailty on chronic HF. Stratification of patients with HF by frailty status provides prognostic information and may inform priorities for HF interventions and management.

Acknowledgments

We thank William B. Goggins III, ScD, of The Chinese University of Hong Kong, for discussions.

Sources of Funding

Bayés-Genís and Gastelurrutia are supported by grants from the Ministerio de Educación y Ciencia (SAF2014-59892) and Generalitat de Catalunya (Pla estratègic de recerca i innovació en salut Programme, Departament de Salut, SLT002_16_00209), Fundació La MARATÓ de TV3 (201502-30, 201516-10), Red de Terapia Celular–TerCel (RD16/0011/0006), and Centro de Investigación en Red en Enfermedades Cardiovasculares (CB16/11/00403) projects as part of the Plan Nacional de I+D+i, and jointly funded by Instituto de Salud Carlos III–Sudirección General de Evaluación y el Fondo Europeo de Desarrollo Regional. Centro Nacional de Investigaciones Cardiovasculares (CNIC) is supported by the Ministerio de Economía, Industria y Competitividad (MINECO), and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (MINECO award SEV-2015-0505). Ferguson was supported by a University of Technology Sydney, Chancellor’s Postdoctoral Research Fellowship (2015001232). Fung is recipient of the Direct Grant award from the Faculty of Medicine, The Chinese University of Hong Kong, and of an investigator-initiated research grant from the Food and Health Bureau of the Hong Kong Special Administrative Region. Woo is supported by research grants from the Hong Kong Jockey Club and the Research Grants Council.

Disclosures

None.

References

1. Morley JE, Vellas B, van Kan GA, Anker SD, Bauer JM, Bernabei R, Cesari M, Chumlea WC, Doehner W, Evans J, Fried LP, Guralnik JM, Katz PR, Malmstrom TK, McCarter RJ, Gutierrez Robledo LM, Rockwood K, van Heelning S, Vandewoude MF, Walston J. Frailty consensus: a call to action. J Am Med Dir Assoc. 2013;14:392–397.

2. Rodríguez-Pascual C, Paredes-Galan E, Ferrero-Martínez AI, Gonzalez-Guerrero JL, Hornillos-Calvo M, Menendez-Colino R, Torres-Torres I, Vilches-Moraga A, Galan MC, Suarez-Garcia F, Olcoz-Chiva MT, Rodriguez-Artalejo F. The frailty syndrome is associated with adverse health outcomes in very old patients with...
stable heart failure: a prospective study in six Spanish hospitals. Int J Cardiol. 2017;236:299–307.

3. Gasteuilruita P, Lupón J, Altittim S, de Antonio M, González B, Cabanes R, Rodríguez M, Urrutia A, Domingo M, Zamora E, Díez C, Coll R, Bayes-Genis A. Frailty is a key determinant of survival in heart failure patients. Int J Cardiol. 2014;175:62–66.

4. Vidón MT, Blaya-Novakova V, Sanchez E, Ortiz J, Serra-Revach JA, Bueno H. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. Eur J Heart Fail. 2016;18:869–875.

5. Boxer R, Kleppinger A, Ahmad A, Annis K, Hager D, Kenny A. The 6-minute walk test is associated with frailty and predicts mortality in older adults with heart failure. Congest Heart Fail. 2010;16:208–213.

6. Cacciatore F, Abete P, Mazzella F, Viati L, Della Morte D, Ambrosio D, Gargiulo G, Testa G, Santis D, Galizia G, Ferrara N, Rengo F. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. Eur J Clin Invest. 2005;35:723–730.

7. McNallan SM, Singh M, Chamberlain AM, Kane RL, Dunlay SM, Redfield MM, Weston SA, Roger VL. Measuring frailty and healthcare utilization among older patients with heart failure in the community. JACC Heart Fail. 2013;1:135–141.

8. Jha SR, Hannu MK, Newton PJ, Wilhelm K, Hayward CS, Jabbour A, Koteyar E, Keog B, Dhital K, Granger E, Connellan M, Jansz P, Spratt PM, Montgomery E, Smith A, Harkess M, Tunicolif P, Davidson PM, Macdonald PS. Reversibility of frailty after bridge-to-implant ventricular assist device implantation or heart transplantation. Transplant Direct. 2017;3:e167.

9. Dunlay SM, Park SJ, Joyce LD, Daly RC, Slulak JM, McNallan SM, Roger VL, Konstam MA. Frailty outcomes after implantation of left ventricular assist device as destination therapy. J Heart Lung Transplant. 2014;33:359–365.

10. McNallan SM, Chamberlain AM, Gerber Y, Singh M, Kane RL, Weston SA, Dunlay SM, Jiang R, Roger VL. Measuring frailty in heart failure: a community perspective. Ann Med. 2013;166:768–774.

11. Madan SA, Fida N, Barman P, Sims D, Shin J, Verghese J, Pina I, Jorde U, Patel SR. Frailty assessment in advanced heart failure. J Card Fail. 2016;22:840–844.

12. Jha SR, Has HS, Hickman LD, Hannu M, Davidson PM, Macdonald PS, Newton PJ. Frailty in advanced heart failure: a systematic review. Heart Fail Rev. 2010;15:553–560.

13. Boxer RS, Dauser DA, Walsh SJ, Hager WD, Kenny AM. The association between vitamin D and inflammation with the 6-minute walk and frailty in patients with heart failure. Am J Geriatr Syst. 2008;56:454–461.

14. Altittim S, Lupón J, González B, Prats M, Parajón T, Urrutia A, Coll R, Valle V. Sex and age differences in fragility in a heart failure population. Eur J Heart Fail. 2005;7:798–802.

15. Lupón J, González B, Santaeugenia S, Altittim S, Urrutia A, Más D, Díez C, Pascual T, Cano L, Valle V. Prognostic implication of frailty and depressive symptoms in an outpatient population with heart failure. Rev Esp Cardiol. 2008;61:835–842.

16. Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM. Multimorbidity, frailty and self-care: important considerations in treatment with anticoagulation drugs: outcomes of the AFASTER study. Eur J Cardiovasc Nurs. 2017;16:113–124.

17. González-Moneo MJ, Sánchez-Benavides G, Verdu-Rotellé JM, Cladellas M, Brugeura J, Quinones-Ubeda S, Enjuanes C, Feliu-Casanova J, Comín-Colet J. Ischemic aetiology, self-reported frailty, and gender with respect to cognitive impairment in chronic heart failure patients. BMC Cardiovasc Disord. 2016;16:163.

18. Denfeld GE, Winters-Stone K, Mudd JO, Hiatt SO, Chien CV, Lee C. Frequency of and significance of physical frailty in patients with heart failure. Am J Cardiol. 2017;119:1243–1249.

19. Khandelwal D, Goel A, Kumar U, Gulati V, Naranj R, Dey AB. Frailty is associated with longer hospital stay and increased mortality in hospitalized older patients. J Nutr Health Aging. 2012;16:732–735.

20. Newman AB, Gottlieb JS, Mcburnie MA, Hirsch CH, Kop WI, Tracy R, Walston JD, Fried LP. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. 2009;64:150–166.

21. Nishiguchi S, Nozaki Y, Yamaji M, Oya K, Hikita Y, Aoyama T, Mabuchi H. Plasma brain natriuretic peptide level in older outpatient with heart failure is associated with physical frailty, especially with the slowness domain. J Geriatr Cardiol. 2016;13:608–614.

22. Parmar KR, Xiu PY, Chowdhury MR, Patel E, Cohen M. In-hospital treatment and outcomes of heart failure in specialist and non-specialist services: a retrospective cohort study in the elderly. Open Heart. 2015;2:e000095.

23. Reeves GR, Whellan DJ, Patel MJ, O’Connor CM, Duncan P, Eggebeen JD, TM, Hewston LA, Pastva AM, Kitzman DW. Comparison of frequency of frailty and severely impaired physical function in patients ≥60 years hospi-
talized with acute decompensated heart failure versus chronic stable heart failure with reduced and preserved left ventricular ejection fraction. Am J Cardiol. 2017;119:1953–1958.

24. Uchmanowicz I, Kusmierz M, Wielik M, Jankowska-Polanska B, Jaroch J, Loboz-Gruzdien K. Frailty syndrome and rehospitalizations in elderly heart failure patients. Aging Clin Exp Res. 2018;30:617–623.

25. Woods NF, LaCroix AZ, Gray SL, Aragaki A, Cochrane BB, Brunner RL, Masaki K, Murray A, Newman AB. Women’s Health Initiative: Frailty: emergence and consequences in women aged 65 and older in the Women’s Health Initiative Observational Study. J Am Geriatr Soc. 2005;53:1321–1330.

26. Yamada S, Kamiya K, Kono Y. Frailty may be a risk marker for adverse outcome in patients with congestive heart failure. ESC Heart Fail. 2015;2:168–170.

27. Gasteuilruita P, Lupón J, Altittim S, de Antonio M, González B, Cabanes R, Cano L, Urrutia A, Domingo M, Zamora E, Díez C, Coll R, Bayes-Genis A. Effect of frailty on quality of life in patients with heart failure. Am J Cardiol. 2013;112:1785–1789.

28. Kenny AM, Boxer R, Walsh S, Hager WD, Raisz LG. Femoral bone mineral density of physical activity in patients with heart failure. Osteoporos Int. 2006;17:420–1427.

29. Pons F, Lupón J, Urrutia A, González B, Crespo E, Díez C, Cano L, Abadines R, Coll R, Pascual T, Valle V. Mortality and cause of death in patients with heart failure: findings at a specialist multidisciplinary heart failure unit. Rev Esp Cardiol. 2010;63:303–314.

30. Uchmanowicz I, Gobbens RJ. The relationship between frailty, anxiety and depression, and health-related quality of life in elderly patients with heart failure. Clin Interv Aging. 2015;10:1595–1606.
Heart Association Older Populations Committee of the Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Stroke Council; American College of Cardiology; and American Geriatrics Society. Knowledge gaps in cardiovascular care of the older adult population: a scientific statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society. Circulation. 2016;133:2103–2122.

43. Jha SR, Hannu MK, Chang S, Montgomery E, Harkess M, Wilhelm K, Hayward CS, Jabbour A, Spratt PM, Newton P, Davidson PM, Macdonald PS. The prevalence and prognostic significance of frailty in patients with advanced heart failure referred for heart transplantation. Transplantation. 2016;100:429–436.

44. Green P, Woglom AE, Genereux P, Daneault B, Paradis JM, Schnell S, Hawkey M, Maurer MS, Kirtane AJ, Kodali S, Moses JW, Leon MB, Smith CR, Williams M. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience. JACC Cardiovasc Interv. 2012;5:974–981.

45. Afilalo J, Lauck S, Kim DH, Lefere T, Piazza N, Martucci G, Lamy R, Rusdi LG, Morin JF, Poppma JJ, Webb JG, Perrault LP. Frailty in older adults undergoing aortic valve replacement: the FRAILTY-AVR study. J Am Coll Cardiol. 2017;70:689–700.

46. McDonagh J, Martin L, Ferguson C, Jha SR, Macdonald PS, Davidson PM, Newton PJ. Frailty assessment instruments in heart failure: a systematic review. Eur J Cardiovasc Nurs. 2017;17:23–35.

47. Bhatia RS, Tu JV, Lee DS, Austin PC, Fung E, Hui E, Gouzi A, Gong Y, Liu PP. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med. 2006;355:260–269.

48. Fung E, Hui E, Yang X, Lui LT, Cheng KF, Leung J, Morley JE. The selection of a screening test for frailty identification in community-dwelling older adults. J Nutr Health Aging. 2014;18:199–203.

49. Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, Woo J, Leung J, Morley JE. Comparison of frailty indicators based on clinical phenotype and the multiple deficit approach in predicting mortality and physical limitation. J Am Geriatr Soc. 2012;60:1478–1486.

50. Chong E, Ho E, Baldevarona-Lego J, Chan M, Wu L, Tay L. Frailty and risk of adverse outcomes in hospitalized adults: a comparison of different frailty measures. J Am Med Dir Assoc. 2017;18:638.e7–638.e11.

51. Auyeung TW, Lee JS, Leung J, Kwok T, Woo J. The impact of frailty status on survival after transcatheter aortic valve replacement in older adults with severe aortic stenosis: a single-center experience. JACC Cardiovasc Interv. 2012;5:974–981.

52. Davis JD, Olsen MA, Bommarito K, LaRue SJ, Saeed M, Rich MW, Vader JM. All-payer analysis of heart failure hospitalization 30-day readmission: comorbidity matters. Am J Med. 2017;130:93.e9–93.e28.

53. Newton PJ, Davidson PM, Reid CM, Krum H, Hayward C, Sibbritt DW, Banks E, MacDonald PS. Acute heart failure admissions in New South Wales and the Australian Capital Territory: the NSW HF Snapshot Study. Med J Aust. 2016;204:113.e1–113.e8.

54. Loop MS, Van Dyke MK, Chen L, Brown TM, Durant RW, Safford MM, Levitan EB. Comparison of length of stay, 30-day mortality, and 30-day readmission rates in Medicare patients with heart failure and with reduced versus preserved ejection fraction. J Am Cardiol. 2016;118:79–85.
SUPPLEMENTAL MATERIAL
Table S1. List of covariates adjusted for in calculating hazard ratios (adjusted hazard ratios).

| Source (First Author [PMID]ref.) | Covariates                                                                                                                                 |
|----------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------|
| Boxer [20887617]¹                 | Age, high-sensitivity C-reactive protein, interleukin-6                                                                                       |
| Cacciatore [16316247]²            | Age, sex, NYHA class, comorbidity, systolic and diastolic blood pressure, HF etiology (i.e. ischemic vs. others), use of diuretics, ACEI, digoxin and nitrates |
| Ferguson [27036952]³              | N/A (only unadjusted hazard ratio available)                                                                                                  |
| Gastelurrutia [24820761]⁴        | Age, sex, HF duration, HF etiology, HF hospitalization, LVEF, NYHA class, number of comorbidities, history of implantable cardioverter defibrillator, use of beta-blockers, ACEI/ARB, mineralocorticoid receptor antagonist, loop diuretics and statin |
| Madan [26883168]⁵                | Age, sex, diabetes mellitus, Charlson comorbidity index                                                                                       |
| McNallan [23956958]⁶             | Age, sex, LVEF, incident and prevalent HF, estimated glomerular filtration rate, history of chronic obstructive pulmonary disease, diabetes mellitus and anemia    |
| McNallan [24093859]⁷             | Age, sex, LVEF                                                                                                                                |
| Rodríguez-Pascual [28215465]⁸    | Age, sex, Charlson comorbidity index, LVEF $\leq$45%, previous HF-related hospitalization other than the index admission, use of ACEI/ARB and beta-blocker |
| Vidán [27072307]⁹               | Age, sex, acute and chronic comorbidities, LVEF, NYHA class, N-terminal pro B-type natriuretic peptide level                                      |

ACEI, Angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; HF, heart failure; LVEF, left ventricular ejection fraction; N/A, not applicable; NYHA, New York Heart Association.

*See also References (Supplemental Material).
Table S2. Actual numbers of deaths and/or hospitalization episodes in chronic heart failure patients with and without frailty.

| Source (First Author [PMID]Ref.) | Sample size, n | Follow-up duration, y | Total | Frail | Non-frail | Hospitalization | Frail | Non-frail |
|----------------------------------|----------------|----------------------|-------|-------|-----------|-----------------|-------|-----------|
| Boxer [20887617]¹               | 59             | 4                    | 33.9  | 60.0  | 25.0      | N/A             | N/A   | N/A       |
| Cacciatore [16316247]²          | 120            | 12                   | 64.2  | 89.6  | 59.8      | N/A             | N/A   | N/A       |
| Ferguson [27036952]³            | 137            | 1                    | 28.6  | 38.5  | 12.5      | 75.0            | 82.7  | 62.5      |
| Gastelurrutia [24820761]⁴       | 1314           | 3.6                  | 47.6  | N/A   | N/A       | N/A             | N/A   | N/A       |
| Madan [26883168]⁵              | 40             | 1.24                 | 25.5  | 30.8  | 14.3      | N/A             | N/A   | N/A       |
| McNallan [23956958]⁶           | 448            | 2.0                  | N/A   | N/A   | N/A       | N/A             | N/A   | N/A       |
| McNallan [24093859]⁷           | 223            | 2.4                  | 28.3  | N/A   | N/A       | N/A             | N/A   | N/A       |
| Rodríguez-Pascual [28215465]⁸  | 497            | 1                    | 19.9  | N/A   | N/A       | 39.4            | N/A   | N/A       |
| Vidán [27072307]⁹             | 416            | 1                    | 22.9  | 25.7  | 11.1      | 61.1            | 63.5  | 53.5      |

N/A, not applicable. PMID, PubMed identifier. Ref., reference number
*See also References (Supplemental Material)
### Table S3. Quality assessment of studies using the Newcastle-Ottawa Scale*.

| Source (First Author [PMID][Ref.]) | Year | Total Score | Score Subtotal | Selection | Comparability | Outcome |
|-----------------------------------|------|-------------|----------------|-----------|---------------|---------|
| Boxer [20887617][1]               | 2010 | 8           | 3              | 0         | 1             | 1       | 2 | 3 | 1 | 1 | 1 |
|                                    |      |             |                | Representative of the exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure to implants | Demonstrate that outcome of interest was not present at start of study | Comparability of cohorts on the basis of design or analysis (variables) | Assessment of outcome | Was follow-up long enough for outcomes to occur? | Adequacy of follow-up of cohorts |
| Cacciatore [16316247][2]          | 2005 | 9           | 4              | 1         | 1             | 1       | 2 | 3 | 1 | 1 | 1 |
| Ferguson [27036952][3]            | 2017 | 7           | 4              | 1         | 1             | 1       | 1 | 0 | 3 | 1 | 1 | 1 |
| Gastelurrutia [24820761][4]       | 2014 | 9           | 4              | 1         | 1             | 1       | 2 | 3 | 1 | 1 | 1 |
| Madan [26883168][5]               | 2016 | 8           | 3              | 1         | 1             | 1       | 0 | 2 | 3 | 1 | 1 | 1 |
| McNallan [23956958][6]            | 2013 | 8           | 3              | 1         | 1             | 1       | 0 | 2 | 3 | 1 | 1 | 1 |
| McNallan                          | 2013 | 9           | 4              | 1         | 1             | 1       | 2 | 3 | 1 | 1 | 1 |
| Study                          | Year | Fragility Score | Frailty Criteria                                                                                                                                                                                                 | Quality Score |
|-------------------------------|------|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|
| Rodriguez-Pascual [28215465]a | 2017 | 9               | Age, sex, Charlson index, LVEF ≤45%, previous HF-related hospitalization other than the index admission, use of ACEI or angiotensin receptor blocker and β-blocker | 3            |
| Vidán [27072307]9            | 2016 | 9               | Age, sex, acute and chronic comorbidities, LVEF, NYHA, NT-proBNP levels                                                                                                                                         | 3            |

ACEI, angiotensin converting enzyme inhibitor; DM, diabetes mellitus; HF, heart failure; LVEF, left ventricular ejection fraction; NT-proBNP, N-terminal prohormone of brain (B-type) natriuretic peptide; NYHA, New York Heart Association functional class.

*Newcastle-Ottawa Scale categorizes the quality of a study based on summed total points: low, 0 to 3 points; intermediate, 4 to 6 points; high, 7 to 9 points.
†Fragility is synonymous with frailty in this study.
‡See also References (Supplemental Material).
Figure S1. Detailed CONSORT-style flow diagram. PubMed unique identifiers shown in squared brackets.
Figure S2. Funnel plots assessing for publication bias in the meta-analyses of frailty on (A) all-cause mortality and (B) incident hospitalization in patients with chronic heart failure. (C) Data on all-cause mortality were further subjected to the Duval-Tweedie’s trim and fill test, demonstrating virtually unchanged effect size estimates and statistical significance (adjusted hazard ratio, 1.48; 95% confidence interval 1.25–1.75, P<0.001).
Supplemental References:

1. Boxer R, Kleppinger A, Ahmad A, Annis K, Hager D, Kenny A. The 6-minute walk is associated with frailty and predicts mortality in older adults with heart failure. *Congest Heart Fail*. 2010; 16:208-213.

2. Cacciatore F, Abete P, Mazzella F, Viati L, Della Morte D, D'Ambrosio D, Gargiulo G, Testa G, Santis D, Galizia G, Ferrara N, Rengo F. Frailty predicts long-term mortality in elderly subjects with chronic heart failure. *Eur J Clin Invest*. 2005; 35:723-730.

3. Ferguson C, Inglis SC, Newton PJ, Middleton S, Macdonald PS, Davidson PM. Multi-morbidity, frailty and self-care: important considerations in treatment with anticoagulation drugs. Outcomes of the AFASTER study. *Eur J Cardiovasc Nurs*. 2017; 16:113-124.

4. Gastelurrutia P, Lupon J, Altimir S, de Antonio M, Gonzalez B, Cabanes R. Rodriguez M, Urrutia A, Domingo M, Zamora E, Diez C, Coll R, Bayes-Genis A. Fragility is a key determinant of survival in heart failure patients. *Int J Cardiol*. 2014; 175:62-66.

5. Madan SA, Fida N, Barman P, Sims D, Shin J, Verghese J, Pina I, Jorde U, Patel SR. Frailty Assessment in Advanced Heart Failure. *J Card Fail*. 2016; 22:840-844.

6. McNallan SM, Singh M, Chamberlain AM, Kane RL, Dunlay SM, Redfield MM, Weston SA, Roger VL. Frailty and healthcare utilization among patients with heart failure in the community. *JACC Heart Fail*. 2013; 1:135-141.

7. McNallan SM, Chamberlain AM, Gerber Y, Singh M, Kane RL, Weston SA, Dunlay SM, Jiang R, Roger VL. Measuring frailty in heart failure: a community perspective. *Am Heart J*. 2013; 166:768-774.

8. Rodriguez-Pascual C, Paredes-Galan E, Ferrero-Martinez AI, Gonzalez-Guerrero JL, Hornillos-Calvo M, Menendez-Colino R, Torres-Torres I, Vilches-Moraga A, Galan MC, Suarez-Garcia F, Olcoz-Chiva MT, Rodriguez-Artalejo F. The frailty syndrome is associated with adverse health outcomes in very old patients with stable heart failure: A prospective study in six Spanish hospitals. *Int J Cardiol*. 2017; 236:296-303.

9. Vidan MT, Blaya-Novakova V, Sanchez E, Ortiz J, Serra-Rexach JA, Bueno H. Prevalence and prognostic impact of frailty and its components in non-dependent elderly patients with heart failure. *Eur J Heart Fail*. 2016; 18:869-875.